AI Article Synopsis
- The paper discusses the challenges in adapting a method for measuring the anticancer drug ES-285 in human plasma using different mass spectrometry equipment, specifically moving from an API 365 to an API 3000.
- Problems during the transfer included issues like carry-over and interferences that complicated the analysis.
- Solutions were found to address these problems, ultimately allowing for a more sensitive detection of ES-285, lowering the quantitation limit from 10 to 1 ng/mL, as demonstrated through patient plasma sample analysis.
Article Abstract
In this paper the transfer of an existing method for the quantitative determination of the anticancer agent ES-285 in human plasma using liquid chromatography tandem mass spectrometry on an API 365 to an API 3000 mass spectrometer is described. The transfer appeared not to be straightforward. Problems arose resulting from carry-over and interferences. In addition, due to the expansion of the calibration range, data ought to be weighted with a different factor to increase the accuracy of the lower concentrations. After finding appropriate solutions for these problems, the lower limit of quantitation could be lowered from 10 to 1 ng/mL for ES-285 in human plasma. The usefulness and necessity of the modified assay was demonstrated by analysis of plasma samples from a patient receiving a low dosage of the drug.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/bmc.404 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!